Navigation Links
Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions -

SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999 will be presented at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO), which is being held June 1 to 5 in Chicago, Illinois.

    -- Data from the Phase I trials of XL880 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics oral

       abstract presentation session at 9:00 a.m. CT on Saturday, June 2, in

       room E354b. (Abstract #3526)


    -- Data from the Phase II trials of XL999 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics poster

       session at 8:00 a.m. on Sunday, June 3, in S Hall A2. (Abstract #3591)


Additionally, four abstracts from Phase I studies of XL184 (Abstract #14031), XL647 (Abstract #14044) and Phase II studies of XL880 (Abstract #15601) and XL999 (Abstract #18112) will be published in abstract form but will not be presented at the meeting.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, , or media, Soleil Maxwell Harrison,Senior Manager, Corporate Communications, +1-650-837-7012, both of Exelixis, Inc. cbutler@exelixis.com sharrison@exelixis.com

Web site: http://www.exelixis.com/

Ticker Symbol: (NASDAQ-NMS:EXEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
2. OXiGENE Abstracts Published in ASCO Program
3. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
5. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
9. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... -- Global Surgical Drainage Device Market: Overview ... excess liquid and air. The fluid to be drained ... Surgical drains are used in a wide variety of ... surgery, neurosurgery, plastic surgery etc. Common use of surgical ... fluid e.g. blood or pus. Surgical drains are available ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus ... that’s the first in a new class of photodynamic cosmetics (PDC). , Allumera® ... skin, visibly reduce outward signs of aging, and minimize the appearance of pores ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent ... test score performance for the 2015-16 school year across Wisconsin’s public schools, charter ... it highlights important patterns in student test score performance, the report’s limited analyses ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
Breaking Medicine News(10 mins):